BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND RHOH, TTF, 399, ENSG00000168421, ARHH, RhoH AND Clinical Outcome
9 results:

  • 1. Thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker?
    La Salvia A; Siciliani A; Rinzivillo M; Verrico M; Baldelli R; Puliani G; Modica R; Zanata I; Persano I; Fanciulli G; Bassi M; Mancini M; Bellino S; Giannetta E; Ibrahim M; Panzuto F; Brizzi MP; Faggiano A
    Endocrine; 2024 Feb; 83(2):519-526. PubMed ID: 37775725
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Skull Base Tumors: Neuropathology and clinical Implications.
    Bi WL; Santagata S
    Neurosurgery; 2022 Mar; 90(3):243-261. PubMed ID: 34164689
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. clinical outcomes of N1b Papillary Thyroid 399FF">cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy.
    Jin M; Ahn J; Lee YM; Sung TY; Kim WG; Kim TY; Ryu JS; Kim WB; Shong YK; Jeon MJ
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):602-609. PubMed ID: 32981302
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Prediction value of XRCC 1 gene polymorphism on the survival of ovarian 399FF">cancer treated by adjuvant chemotherapy.
    Miao J; Zhang X; Tang QL; Wang XY; Kai L
    Asian Pac J Cancer Prev; 2012; 13(10):5007-10. PubMed ID: 23244100
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Association between polymorphisms of XRCC1 and ADPRT genes and ovarian 399FF">cancer survival with platinum-based chemotherapy in Chinese population.
    Li K; Li W
    Mol Cell Biochem; 2013 Jan; 372(1-2):27-33. PubMed ID: 22983827
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
    Pape UF; Berndt U; Müller-Nordhorn J; Böhmig M; Roll S; Koch M; Willich SN; Wiedenmann B
    Endocr Relat Cancer; 2008 Dec; 15(4):1083-97. PubMed ID: 18603570
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases.
    Thompson LD; Wieneke JA; Heffess CS
    Endocr Pathol; 2005; 16(4):331-48. PubMed ID: 16627920
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic 399FF">cancer.
    Ko AH; Hwang J; Venook AP; Abbruzzese JL; Bergsland EK; Tempero MA
    Br J Cancer; 2005 Jul; 93(2):195-9. PubMed ID: 15999098
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.